



Company Information Center

February 3, 2005 US Eastern Time zone

VERTEBRON™ INC. ANNOUNCES THE RELEASE OF ITS FIRST ALLOGRAFT, VERTEBRON PLF™ ALLOGRAFT SYSTEM, AND ITS ABILITY TO PROVIDE COMPLETE LUMBAR SPINE SOLUTIONS.

STRATFORD, Conn.—February 3, 2005—VERTEBRON Inc. (VERTEBRON) is proud to announce the release of its first structural allograft, the VERTEBRON PLF Allograft System, its third system release. VERTEBRON is now able to provide more complete solutions for spine surgeons, consisting of both metal and biologic implants promoting lumbar fusion. The PLF system is the first allograft released by VERTEBRON in collaboration with US Tissue and Cell (UST&C) which has entered into a letter of intent to be purchased by Bacterin International, Inc. Future releases including an ACIF allograft and additional base bone options (including structural and void filling applications) are planned for release within the upcoming months.

The PLF system incorporates many patent-pending features, including elliptical anti-migration features addressing both A-P and M-L shifts within a unique design and optimized footprint. Using simplified instrumentation, machined anatomic, lordotic allografts are posteriorly positioned using a profiled inserter designed to minimize retraction and the potential for nerve injury.

Within the last 2 months, the VERTEBRON PLF Allograft System was successfully used in several procedures in domestic surgery centers. Dr. Jeffrey Donner, at McKee Medical Center in Loveland, Colorado, used the PLF allograft system for several thoracolumbar fusion procedures and commented, “VERTEBRON’s PLF allograft system is based on clever designs which meet surgeon’s expectations while providing simple, easy to use instrumentation.” Surgeries were also performed at Summit Medical Center in Nashville, TN by Dr. T. Elalayli from the Southern Spine Center who also serves as faculty at Vanderbilt University. Dr. Elalayli confirmed, “VERTEBRON’s PLF system is well engineered and easy to use. The instrumentation provides for easy endplate preparation and bone graft insertion.” Additional surgery centers are currently evaluating the PLF Allograft System.

Hosam Afifi, President and CEO for VERTEBRON commented, “The favorable responses VERTEBRON has received in connection with all of our system releases are a testament to our design philosophy focused on simplifying surgical techniques and providing innovative integrated instrumentation. With the PLF system release, surgeons are now offered allograft options, designed to work in concert with our Pedicle Screw System (PSS™), thereby providing more complete lumbar spine solutions. For VERTEBRON, 2005 will be a milestone year on many fronts, expanding our reach to more surgeons and markets worldwide with both biologic and other strategic alliances which will keep us ahead of the curve in this rapidly expanding market. VERTEBRON is especially proud to be strategically aligned with UST&C’s superior quality products and its new parent, Bacterin. We hope to further develop our technology partnership with Bacterin through novel biological applications.”

VERTEBRON is a closely-held, medical device company that has developed spinal implants, including artificial discs (motion preservation), cervical plates, pedicle screw and interbody (fusion) systems through the integration of spinal, orthopaedic and total joint technologies. VERTEBRON’s advanced motion preservation devices, fusion technologies and breakthrough spinal implant designs are strategically positioned to establish the company as a leading provider of next-generation spinal surgery solutions. VERTEBRON’s comprehensive product portfolio offers simplified surgical techniques, enhanced intra-operative flexibility and innovative instrumentation to spine surgeons worldwide. For more information, please visit www.VERTEBRON.com.

Any statements in this press release about future expectations, plans and prospects for the Company, including statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, risks and uncertainties. These statements are subject to change based on risks detailed from time to time in VERTEBRON’s Business Plan and stock offering documents and other known and unknown risks and factors, which could cause the actual results or performance to differ materially from the statements made. Do not place undue reliance on forward-looking statements, which reflect our analysis only and speak only as of the date hereof.

Contacts: VERTEBRON Inc., Anan Natarajan 203/380-9340